Disclosure Of Entity's Operating Segments [Text Block]

OSE Immunotherapeutics - Filing #2813125

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
18 302 EUR
26 306 EUR
Tax expense (income)
263,000 EUR
364,000 EUR
Profit (loss) before tax
18 022 EUR
17 213 EUR
Profit (loss)
17 760 EUR
17 760 EUR
16 850 EUR
16 850 EUR
Assets
91 781 EUR
101 876 EUR
Cash flows from (used in) operating activities
18 252 EUR
9 919 EUR
Cash flows from (used in) investing activities
26,000 EUR
827,000 EUR
Cash flows from (used in) financing activities
10 267 EUR
14 957 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.